Core Viewpoint - Cybin Inc. is under investigation by the Schall Law Firm for potential violations of securities laws, particularly regarding misleading statements and failure to disclose important information to investors [2]. Company Summary - The investigation is focused on whether Cybin issued false or misleading statements or failed to disclose relevant information to investors [2]. - Following the announcement of CEO Doug Drysdale's resignation on September 2, 2025, Cybin's shares dropped by over 16.5% on the same day [2]. Legal Context - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3].

Core Viewpoint - The Schall Law Firm is investigating potential breaches of fiduciary duty by the directors and management of Olo Inc. in relation to its acquisition by Thoma Bravo for $10.25 per share [1]. Group 1 - The investigation by the Schall Law Firm focuses on whether the Olo board acted in the best interests of its shareholders during the acquisition process [1]. - Olo Inc. has agreed to be acquired by Thoma Bravo at a price of $10.25 per share [1].

Core Viewpoint - The Schall Law Firm is investigating Quipt Home Medical Corp. for potential violations of securities laws, particularly concerning misleading statements and failure to disclose important information to investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Quipt issued false or misleading statements, particularly regarding a press release on May 21, 2025, related to an acquisition offer from Forager Capital Management [2]. - Forager Capital Management, a significant shareholder, has requested Quipt to retract its misleading statement about their offer to acquire 100% of Quipt's common shares at a price of $3.10 per share [2]. - Following the news of the investigation and the press release from Forager, Quipt's shares experienced a decline of over 8.5% on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who have suffered losses are encouraged to contact the Schall Law Firm for a free discussion of their rights [3].

LOS ANGELES, June 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it has filed a class action lawsuit in the United States District Court for the District of Oregon (Portland Division), captioned Ullom v. Digimarc Corporation, et al., Case No. 3:25-cv-00779-JR, on behalf of persons and entities that purchased or otherwise acquired Digimarc Corporation ("Digimarc" or the "Company") (NASDAQ: DMRC) securities between May 3, 2024 and February 26, 2025, ...

Core Viewpoint - A class action lawsuit has been filed against Merck & Co., Inc. for alleged violations of securities laws, specifically related to misleading statements about the demand for its product Gardasil in China and inflated inventory issues [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Merck's securities between February 3, 2022, and February 3, 2025, are encouraged to participate in the class action [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Merck - The complaint alleges that Merck made false and misleading statements regarding its consumer activation and education efforts for Gardasil, particularly in China [4]. - The company was overly optimistic about Gardasil's demand while concealing negative facts about actual demand and inflated inventory held by its distributor, Zhifei [4]. - As a result of these misleading statements, investors suffered damages when the truth about Merck's situation was revealed [4].

Group 1 - The Schall Law Firm has initiated a class action lawsuit against Merck & Co., Inc. for alleged violations of the Securities Exchange Act of 1934 [1][4] - The lawsuit pertains to investors who purchased Merck's securities between February 3, 2022, and February 3, 2025, and encourages them to contact the firm before April 14, 2025 [2] - The complaint alleges that Merck made false and misleading statements regarding the demand for its product Gardasil, particularly in China, while concealing negative facts about inventory levels [4] Group 2 - The lawsuit claims that Merck's public statements were materially misleading, leading to investor damages when the truth about the company's situation was revealed [4] - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [5]

Core Viewpoint - The Schall Law Firm is investigating Lineage, Inc. for potential violations of securities laws, particularly regarding misleading statements and undisclosed information that may have affected investors [1][2]. Group 1: Investigation Details - The investigation is centered on whether Lineage issued false or misleading statements and failed to disclose critical information to investors [2]. - Lineage has experienced multiple analyst downgrades attributed to its weak financial performance in 2024 [2]. Group 2: Investor Participation - Shareholders who have incurred losses are encouraged to participate in the investigation [2]. - The Schall Law Firm offers free consultations to discuss the rights of affected investors [3].